Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALNY Alnylam Pharmaceuticals

Closed Independence Day 07-02 16:00:00 EDT

312.78

+11.11

+3.68%

盘后312.78

+0.000.00%

19:51 EDT

High317.17	Low303.00	Vol1.09M
Open303.87	D1 Closing301.67	Amplitude4.70%
Mkt Cap41.73B	Tradable Cap39.46B	Total Shares133.43M
T/O341.51M	T/O Rate0.87%	Tradable Shares126.15M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ALNY","market":"US","secType":"STK","nameCN":"Alnylam Pharmaceuticals","latestPrice":312.78,"timestamp":1783022400000,"preClose":301.67,"halted":0,"volume":1093490,"hourTrading":{"tag":"盘后","latestPrice":312.78,"preClose":312.78,"latestTime":"19:51 EDT","volume":48587,"amount":15197321.84,"timestamp":1783036271335,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.036828322338979536,"floatShares":126154848,"shares":133427910,"eps":4.0295005,"marketStatus":"Closed Independence Day","change":11.11,"latestTime":"07-02 16:00:00 EDT","open":303.87,"high":317.17,"low":303,"amount":341507315.15500003,"amplitude":0.046972,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":4.0295005,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1783324800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1085630400000,"exchange":"NASDAQ","adjPreClose":301.67,"preHourTrading":{"tag":"盘前","latestPrice":302.51,"preClose":301.67,"latestTime":"09:26 EDT","volume":229,"amount":69410.6328,"timestamp":1782998792247,"change":0.84,"changeRate":0.002784,"amplitude":0.019259},"postHourTrading":{"tag":"盘后","latestPrice":312.78,"preClose":312.78,"latestTime":"19:51 EDT","volume":48587,"amount":15197321.84,"timestamp":1783036271335,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8452901489991642,"impliedVol":0.4692,"impliedVolPercentile":0.741},"requestUrl":"/m/hq/s/ALNY/wiki","defaultTab":"wiki","newsList":[{"id":"1198755198","title":"Movement Alert｜Alnylam Pharmaceuticals Rises 5.01% in Regular Trading, Multiple Partnership Catalysts Fuel Rally Amid Biotech Sector Strength","url":"https://stock-news.laohu8.com/highlight/detail?id=1198755198","media":"Market Focus","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198755198?lang=en_us&edition=fundamental","pubTime":"2026-07-02 23:01","pubTimestamp":1783004471,"startTime":"0","endTime":"0","summary":"On July 2, Alnylam Pharmaceuticals rose 5.01% in regular trading, trading at $317.17/share, with turnover of $69.34 million.The rally was fueled by a series of recent strategic partnership...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647375106","title":"Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Biohaven Ltd. (BHVN) and Praxis Precision Medicines (PRAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2647375106","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647375106?lang=en_us&edition=fundamental","pubTime":"2026-06-29 18:50","pubTimestamp":1782730248,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alnylam Pharma (ALNY), Biohaven Ltd. (BHVN) and Praxis Precision ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alnylam-pharma-alny-biohaven-ltd-bhvn-and-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alnylam-pharma-alny-biohaven-ltd-bhvn-and-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU0882574055.USD","LU1093756168.USD","LU0029874061.USD","BK4548","LU0114720955.EUR","BK4581","XLV","ALNY","IE0009355771.USD","BK4139","LU0320765992.SGD","BK4588","PRAX","LABU","IE00B4R5TH58.HKD","LU0109394709.USD","LU0889565916.HKD","BHVN","IE00BFTCPJ56.SGD","XBI","BK4585","IE00BJJMRZ35.SGD","HCSG","LU1093756325.SGD","LU0128526141.USD","IE0002141913.USD","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647873373","title":"Alnylam Pharmaceuticals is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2647873373","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647873373?lang=en_us&edition=fundamental","pubTime":"2026-06-29 18:21","pubTimestamp":1782728460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALNY/analyst-ratings(END) Dow Jones NewswiresJune 29, 2026 06:21 ET","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647783383","title":"Alnylam Pharmaceuticals, Inc. : H.c. Wainwright Cuts Target Price to $470 from $510","url":"https://stock-news.laohu8.com/highlight/detail?id=2647783383","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647783383?lang=en_us&edition=fundamental","pubTime":"2026-06-29 18:01","pubTimestamp":1782727283,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nAZN4T4WON:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4548","LU0320765992.SGD","LU0889565916.HKD","LU0109394709.USD","LU0882574055.USD","LU0114720955.EUR","BK4585","BK4588","BK4139","ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647785483","title":"Alnylam price target lowered to $470 from $510 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2647785483","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647785483?lang=en_us&edition=fundamental","pubTime":"2026-06-29 18:00","pubTimestamp":1782727211,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on Alnylam (ALNY) to $470 from $510 and keeps a Buy rating on the shares. The firm reduced its near...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alnylam-price-target-lowered-to-470-from-510-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alnylam-price-target-lowered-to-470-from-510-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0882574055.USD","BK4139","LU0889565916.HKD","ALNY","BK4588","LU0109394709.USD","LU0320765992.SGD","LU0114720955.EUR","BK4585","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647378316","title":"Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Cytokinetics (CYTK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2647378316","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647378316?lang=en_us&edition=fundamental","pubTime":"2026-06-29 17:40","pubTimestamp":1782726017,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alnylam Pharma (ALNY) and Cytokinetics (CYTK) with b...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alnylam-pharma-alny-and-cytokinetics-cytk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alnylam-pharma-alny-and-cytokinetics-cytk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","BK4139","LU0320765992.SGD","LU0029874061.USD","LU0128526141.USD","ALNY","LU0882574055.USD","HCSG","LU0889565916.HKD","BK4588","BK4585","LU0114720955.EUR","BK4548","XLV","BK4505","LABU","BK4137","XBI","LU0109394709.USD","CYTK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647203763","title":"Alnylam Pharma (ALNY) Receives a Buy from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2647203763","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647203763?lang=en_us&edition=fundamental","pubTime":"2026-06-29 17:26","pubTimestamp":1782725174,"startTime":"0","endTime":"0","summary":"In a report released today, Eliana Merle from Barclays maintained a Buy rating on Alnylam Pharma, with a price target of $527.00. According to TipR...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/alnylam-pharma-alny-receives-a-buy-from-barclays-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/alnylam-pharma-alny-receives-a-buy-from-barclays-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0882574055.USD","ALNY","LU0114720955.EUR","BK4139","LU0109394709.USD","BK4588","BK4548","BK4585","LU0889565916.HKD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647732913","title":"U.S. Research Roundup-3m Co, Nike, Primoris Services","url":"https://stock-news.laohu8.com/highlight/detail?id=2647732913","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647732913?lang=en_us&edition=fundamental","pubTime":"2026-06-29 15:28","pubTimestamp":1782718137,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-3M Co, Nike, Primoris ServicesJune 29 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including 3M Co, Nike an","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nL4N4310H5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACI","RVMD","IE00BGHQDM52.EUR","SYNA","BK4134","LU1496350502.SGD","LU2360106947.USD","QCOM","AADX","LU2362541513.USD","PRAX","TECH","QCMU","SG9999001424.SGD","LU2092937221.SGD","BK4573","LU0648001328.SGD","WDCX","GPK","MKC","IE00BJJMRZ35.SGD","INIO","LU2237957902.USD","SG9999015945.SGD","WULF","WULX","LU2298321311.HKD","SSMR","WDC","LU1894683264.USD","LFTO","BK4009","ALGM","HONA","QNT","IE00B19Z9P08.USD","LU0154236417.USD","QCML","LEVI","LU2404859741.USD","NKE","PRIM","STZ","LU1267930227.SGD","ALNY","IE0002141913.USD","BIIB","QCMD","MMM","CMCSA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646335432","title":"Alnylam Posts Aln-6400 Plasminogen-targeting Rnai Therapy Presentation on Rare Bleeding Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2646335432","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646335432?lang=en_us&edition=fundamental","pubTime":"2026-06-26 12:10","pubTimestamp":1782447015,"startTime":"0","endTime":"0","summary":"Alnylam posts ALN-6400 plasminogen-targeting RNAi therapy presentation on rare bleeding disordersAlnylam published a medical research presentation on ALN-6400, an investigational RNAi therapy designed","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDL7mFPCQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4139","BK4585","LU0109394709.USD","ALNY","LU0882574055.USD","BK4548","LU0320765992.SGD","BK4588","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646803605","title":"Komodo Health Expands Strategic Partnership with Alnylam to Scale Marmot AI Analytics Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2646803605","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646803605?lang=en_us&edition=fundamental","pubTime":"2026-06-25 21:01","pubTimestamp":1782392512,"startTime":"0","endTime":"0","summary":"Komodo Health expands strategic partnership with Alnylam to scale Marmot AI analytics platformAlnylam expanded a strategic partnership with Komodo Health to scale the Marmot analytics AI platform acro","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nNDL5B6GfX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","ALNY","LU0889565916.HKD","BK4139","LU0114720955.EUR","BK4585","LU0109394709.USD","LU0320765992.SGD","BK4588","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646708068","title":"Oppenheimer Sticks to Their Buy Rating for Alnylam Pharma (ALNY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2646708068","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646708068?lang=en_us&edition=fundamental","pubTime":"2026-06-25 19:56","pubTimestamp":1782388561,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst Kostas Biliouris reiterated a Buy rating on Alnylam Pharma today and set a price target of $500.00. Biliouris covers the Health...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oppenheimer-sticks-to-their-buy-rating-for-alnylam-pharma-alny-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oppenheimer-sticks-to-their-buy-rating-for-alnylam-pharma-alny-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALNY","OPY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176526762","title":"Movement Alert｜Alnylam Pharmaceuticals Rises 5.1% in Regular Trading, Trading at $302.29","url":"https://stock-news.laohu8.com/highlight/detail?id=1176526762","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176526762?lang=en_us&edition=fundamental","pubTime":"2026-06-25 00:52","pubTimestamp":1782319951,"startTime":"0","endTime":"0","summary":"On June 24, Alnylam Pharmaceuticals rose 5.1% in regular trading, trading at $302.29/share, with Turnover of $156 million.Within the Biotechnology sector where Alnylam Pharmaceuticals belongs,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645141021","title":"Regeneron Gets FDA, EMA Review of Cemdisiran in Generalized Myasthenia Gravis","url":"https://stock-news.laohu8.com/highlight/detail?id=2645141021","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645141021?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:33","pubTimestamp":1782127980,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals said U.S. and European regulators have accepted its applications seeking approval of its cemdisiran drug candidate in the rare and chronic autoimmune disease generalized myasthenia gravis, or gMG.Regeneron on Monday said the U.S. Food and Drug Administration and the European Medicines Agency will review cemdisiran to for adults with gMG who are anti-acetylcholine receptor antibody-positive.The Tarrytown, N.Y., biotechnology company said the FDA has granted the application priority review, which shortens the review period, and that it set a target action date in November.Regeneron, which is developing cemdisiran under a licensing agreement with Alnylam Pharmaceuticals, said it expects a decision from the European Commission in the second half of 2027.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","LU2362541273.HKD","LU2023250504.SGD","LU2106854487.HKD","LU2089984988.USD","LU0823434740.USD","LU1917777945.USD","LU2468319806.SGD","LU0882574055.USD","BK4588","LU0109394709.USD","LABU","LU0889565916.HKD","LU0053666078.USD","BK4139","LU0823434583.USD","LU2237438978.USD","LU0320765992.SGD","LU1974910355.USD","LU0114720955.EUR","BK4548","REGN","LU0289739699.SGD","BK4585","LU2362540622.SGD","LU0058720904.USD","ALNY","EMA","BK4081","LU2362541513.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645804032","title":"Barclays Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645804032","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645804032?lang=en_us&edition=fundamental","pubTime":"2026-06-22 16:38","pubTimestamp":1782117521,"startTime":"0","endTime":"0","summary":"In a report released today, Eliana Merle from Barclays maintained a Buy rating on Alnylam Pharma, with a price target of $527.00. According to TipR...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-reaffirms-their-buy-rating-on-alnylam-pharma-alny-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-reaffirms-their-buy-rating-on-alnylam-pharma-alny-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645965017","title":"RBC Capital Remains a Buy on Alnylam Pharma (ALNY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645965017","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645965017?lang=en_us&edition=fundamental","pubTime":"2026-06-22 09:45","pubTimestamp":1782092713,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Luca Issi maintained a Buy rating on Alnylam Pharma on June 18 and set a price target of $445.00. The company’s shares closed l...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-alnylam-pharma-alny-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-alnylam-pharma-alny-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0114720955.EUR","ALNY","LU0310800379.SGD","LU0882574055.USD","BK4139","LU0109394709.USD","BK4207","LU0708994859.HKD","LU1267930573.SGD","LU0320765992.SGD","BK4585","LU0128525929.USD","LU0889565916.HKD","BK4548","LU0029864427.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644823120","title":"BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EDT on 2026-06-18","url":"https://stock-news.laohu8.com/highlight/detail?id=2644823120","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644823120?lang=en_us&edition=fundamental","pubTime":"2026-06-18 23:01","pubTimestamp":1781794882,"startTime":"0","endTime":"0","summary":"BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EDT on 2026-06-18Nasdaq 100 .NDXTop PerformersPercent ChangeMarvell Technology Inc MRVL.OQ+12.0%Sandisk Corp SNDK.OQ+10.7%Western Digital Corp WDC.OQ+8.8%Micron Technology Inc MU.OQ+8.2%Intel Corp INTC.OQ+8.1%Bottom PerformersPercent ChangeCognizant Technology Solutions Corp CTSH.OQ-7.2%Alnylam Pharmaceuticals Inc ALNY.OQ-3.3%Datadog Inc DDOG.OQ-2.5%Palantir Technologies Inc PLTR.OQ-2.5%Baker Hughes Co BKR.OQ-2.5%The Nasdaq 100 .NDX gained 632.22 points, or 2.13%, to 30,303.17 and recorded 10 new highs and 8 new lows. 65 stocks rose and 36 fell as advancing issues outnumbered decliners by a about a 1.8-to-1 ratio.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nL8N42Q1GD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0096364046.USD","LU0048573561.USD","04335","LU0702159343.USD","BK4515","PLTI","BK4553","LU0823421416.USD","IE00BMPRXN33.USD","LU2290526834.HKD","LU1868836914.USD","LU0197229882.USD","LU0642271901.SGD","LU1917777945.USD","PLTD","LU0889565916.HKD","BK4554","LU0149725797.USD","LU0072462343.USD","IE00BLSP4239.USD","LU0708995666.HKD","LU1861558580.USD","LU2543165471.USD","LU2720916845.USD","LU2764263039.SGD","PLTA","LU2286300806.USD","MUU","BK4179","BK4581","BK4607","LU1261432733.SGD","LU1861215975.USD","LU0056508442.USD","IE00B19Z9P08.USD","LU0274383776.USD","LU2272731600.USD","LU2360106780.USD","LU1861220033.SGD","IE00B7SZLL34.SGD","LU2106854487.HKD","PLT","LU1989764664.SGD","LU1823568750.SGD","BK4585","IE00B5949003.HKD","LU0203347892.USD","LU1720051108.HKD","LU2931357623.SGD","IE00BMPRXR70.SGD","LU1064131342.USD","LU0742534661.SGD","LU2250418816.HKD","LU1169589451.USD","MRVU","BK4134","LU1048588211.SGD","IE00B19Z9Z06.USD","LU1119994496.HKD","LU2148611432.USD","PLTG","WDCX","IE00BK4W5M84.HKD","LU0251142724.SGD","LU1720051017.SGD","BK4532","LU1992135472.HKD","MULL","LU1992135399.USD","BK4139","LU0719512351.SGD","LU2458330169.SGD","LU0256331488.USD","DOGD","BK4141","LU0823434583.USD","LU1267930656.SGD","LU0109392836.USD","IE0002270589.USD","LU1267930813.SGD","MUD","LU0321505439.SGD","LU1069347547.HKD","LU1235294995.USD","LU0476273544.USD","LU0787776722.HKD","IE00B19Z3581.USD","LU1366333091.USD","LU0097036916.USD","LU2357305700.SGD","PLTY","SNDK","LU0082616367.USD","BK4566","LU2506951958.HKD","BK4533","LU1805238398.USD","LU2360107168.USD","ALNY","BK4543","MVLL","BK4575","LU1548497426.USD","LU1815336760.USD","LU2750360641.GBP","LU1166156734.SGD","LU1803068979.SGD","LU0011850046.USD","LU1169590202.USD","BK4534","INTC","LU2750360997.AUD","LU0162691827.USD","LU0187121727.USD","BK4547","LU2764262908.HKD","LU1323610961.USD","LU0683600562.USD","LU2471134523.USD","LU2471134952.CNY","SNDU","LU2023250504.SGD","LU1046421795.USD","MU","BK4023","LU0444973449.USD","IE00BN8TJ469.HKD","LU2089985449.USD","IE00BZ9MQY76.HKD","LU1852331112.SGD","LU2471134879.HKD","LU0072461881.USD","LU0702159699.USD","LINT","LU0157215616.USD","LU1974910355.USD","BK4535","LU0950375773.USD","LU0109394709.USD","LU0287143357.SGD","LU0823434740.USD","LU1084165304.USD","LU1861559042.SGD","LU1868837136.USD","LU0231203729.USD","LU2023250843.SGD","LU2244417387.USD","PLTR","BK4170","HK0000304805.HKD","LU0536402901.SGD","PTIR","LU2098885051.SGD","LU0823417653.USD","LU0127658192.USD","BK4548","SNXX","LU2272731782.SGD","LU2473716301.USD","LU2272731865.HKD","LU2463526074.USD","BK4579","BK4588","BK4605","LU0889566641.SGD","BK4561","LU0114720955.EUR","GB00BDT5M118.USD","INTW","LU0321505868.SGD","BK4512","LU2506952097.USD","WDC","LU2322448957.HKD","BK4602","BK4613","BK4528","IE0009356076.USD","LU0211331839.USD","LU2764263203.CNY","LU0054578231.USD","LU0963586101.USD","LU2322448791.USD","CTSH","LU2506952170.USD","IE00BBT3K403.USD","LU0792757196.USD","LU2048586759.USD","PLTU","IE00B894F039.SGD","LU0154236417.USD","IE00BK4W5L77.USD","LU1316542783.SGD","BK4604","PLTW","LU1303367103.USD","LU1914381329.SGD","IE000M9KFDE8.USD","LU0238689110.USD","LU2357627491.SGD","LU0786609619.USD","LU0154245756.USD","LU1153585028.USD","LU2087621335.USD","LU0882574055.USD","LU2506951875.HKD","LU0889565833.HKD","PLYY","LU0061475181.USD","LU0823421333.USD","SG9999000418.SGD","LU0821914370.USD","LU1868837300.USD","BK4612","LU2471134796.USD","LU1988902786.USD","IE00B19Z3B42.SGD","LU1868836591.USD","PLOO","HK0000304797.USD","LU2054465674.USD","LU0006061336.USD","IE00BLSP4452.SGD","LU0251131958.USD","LU0203345920.USD","DDOG","LU1989764748.USD","LU1642822529.SGD","BK4551","BK4529","LU2264538146.SGD","LU0957808578.USD","BK4550","MRVL","BKR","LU0320765992.SGD","LU2458330243.SGD","LU1048596156.SGD","LU0859254822.USD","BK4527","LU0823417737.USD","SG9999001424.SGD","LU0444971666.USD","PLTZ","LU0154245673.USD","LU2211815571.USD","LU1839511570.USD","LU0081259029.USD","LU1868836757.USD","LU1035773651.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643659797","title":"Does Alnylam’s Generative AI Pact With Inceptive Nucleics Redraw The R&D Bull Case For ALNY?","url":"https://stock-news.laohu8.com/highlight/detail?id=2643659797","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643659797?lang=en_us&edition=fundamental","pubTime":"2026-06-16 21:33","pubTimestamp":1781616828,"startTime":"0","endTime":"0","summary":"In early June 2026, Inceptive Nucleics announced a collaboration with Alnylam Pharmaceuticals worth up to US$2.00 billion, including US$30 million in upfront cash and equity, to integrate generative AI models into Alnylam’s RNAi drug discovery engine while Alnylam also broadened its European commercial reach via GENESIS Pharma.\nA distinctive aspect of this alliance is Alnylam’s access to Inceptive’s frontier AI talent, including the co-inventor of the Transformer architecture, aimed at using...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/does-alnylams-generative-ai-pact-with-inceptive-nucleics-red","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/does-alnylams-generative-ai-pact-with-inceptive-nucleics-red","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0109394709.USD","LU0320765992.SGD","BK4543","LU0114720955.EUR","ALNY","BK4587","BK4023","BK4528","AIYY","ARTY","LU0889565916.HKD","BK4551","AGIX","BK4139","BK4585","BK4588","AI","LU0882574055.USD","CHAT","BK4548","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642293473","title":"Alnylam to host 10th RNAi Roundtable webcast series on pipeline updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2642293473","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642293473?lang=en_us&edition=fundamental","pubTime":"2026-06-12 21:00","pubTimestamp":1781269228,"startTime":"0","endTime":"0","summary":"Alnylam will host its 10th RNAi Roundtable webcast series, starting June 25 at 11:00 a.m. ET.Later sessions are scheduled for Sept. 17 at 10:30 a.m. ET, followed by Oct. 26 at 10:00 a.m. ET.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDL857zNg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4139","BK4585","LU0109394709.USD","ALNY","LU0882574055.USD","BK4548","LU0320765992.SGD","BK4588","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642669425","title":"Alnylam, Genesis Pharma Expand Commercial Partnership Into 4 Nordic Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2642669425","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642669425?lang=en_us&edition=fundamental","pubTime":"2026-06-10 20:05","pubTimestamp":1781093111,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals  and Genesis Pharma agreed to expand their commercial partnership to include Denmark, Finland, Norway and Sweden, Genesis said Wednesday.The collaboration already covers 13 markets in Southeast Europe, including Greece, Bulgaria, Romania, Croatia, and Serbia.Under the expanded agreement, Genesis Pharma will receive rights to commercialize Alnylam's portfolio of RNA interference therapeutics for serious cardiomyopathy conditions and rare genetic diseases across the four Nordic markets.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LU0882574055.USD","LU0889565916.HKD","ALNY","BK4585","BK4588","LU0109394709.USD","LU0320765992.SGD","LU0114720955.EUR","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642423271","title":"Genesis Pharma: Extended Agreement With Alnylam Pharmaceuticals NOW Includes Denmark, Finland, Norway, and Sweden","url":"https://stock-news.laohu8.com/highlight/detail?id=2642423271","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642423271?lang=en_us&edition=fundamental","pubTime":"2026-06-10 19:47","pubTimestamp":1781092036,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nFWN42I0CG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0109394709.USD","BK4139","LU0889565916.HKD","BK4548","LU0882574055.USD","BK4588","LU0114720955.EUR","LU0320765992.SGD","BK4585","ALNY"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alnylam.com","stockEarnings":[{"period":"1week","weight":0.0669},{"period":"1month","weight":0.0932},{"period":"3month","weight":-0.019},{"period":"6month","weight":-0.2184},{"period":"1year","weight":-0.0515},{"period":"ytd","weight":-0.2134}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":-0.0195},{"period":"3month","weight":0.1356},{"period":"6month","weight":0.0902},{"period":"1year","weight":0.2004},{"period":"ytd","weight":0.0922}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.028609},{"month":2,"riseRate":0.454545,"avgChangeRate":0.002754},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.012836},{"month":4,"riseRate":0.363636,"avgChangeRate":-0.021744},{"month":5,"riseRate":0.590909,"avgChangeRate":0.038262},{"month":6,"riseRate":0.608696,"avgChangeRate":0.061553},{"month":7,"riseRate":0.695652,"avgChangeRate":0.103973},{"month":8,"riseRate":0.590909,"avgChangeRate":0.037005},{"month":9,"riseRate":0.545455,"avgChangeRate":0.034409},{"month":10,"riseRate":0.409091,"avgChangeRate":-0.042013},{"month":11,"riseRate":0.727273,"avgChangeRate":0.078577},{"month":12,"riseRate":0.454545,"avgChangeRate":0.006257}],"exchange":"NASDAQ","name":"Alnylam Pharmaceuticals","nameEN":"Alnylam Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Alnylam Pharmaceuticals(ALNY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Alnylam Pharmaceuticals,ALNY,Alnylam Pharmaceuticals股票,Alnylam Pharmaceuticals股票老虎,Alnylam Pharmaceuticals股票老虎国际,Alnylam Pharmaceuticals行情,Alnylam Pharmaceuticals股票行情,Alnylam Pharmaceuticals股价,Alnylam Pharmaceuticals股市,Alnylam Pharmaceuticals股票价格,Alnylam Pharmaceuticals股票交易,Alnylam Pharmaceuticals股票购买,Alnylam Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Alnylam Pharmaceuticals(ALNY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}